Harry Gillis
Stock Analyst at Berenberg Bank
(3.52)
# 2,176
Out of 4,408 analysts
67
Total ratings
51.1%
Success rate
8.9%
Average return
Main Sectors:
Stocks Rated by Harry Gillis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STO: SOBI Swedish Orphan Biovitrum AB (publ) | Maintained: Buy | kr 515.00 → kr 525.00 | $435.00 | +20.69% | 18 | May 27, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 → $140 | $90.80 | +54.19% | 12 | May 11, 2026 | |
| ETR: SRT3 Sartorius Aktiengesellschaft | Upgraded: Buy | €215.00 → €250.00 | $229.00 | +9.17% | 3 | Apr 24, 2026 | |
| SWX: TECN Tecan Group AG | Maintained: Buy | CHF 205.00 | $149.20 | +37.40% | 7 | Apr 21, 2026 | |
| ATAI AtaiBeckley | Maintained: Buy | $13 → $14 | $3.84 | +264.58% | 10 | Apr 20, 2026 | |
| QGEN Qiagen | Maintained: Buy | $53 → $58 | $37.01 | +56.38% | 7 | Feb 12, 2026 | |
| MRNA Moderna | Maintained: Hold | $26 → $32 | $52.13 | -38.62% | 10 | Jan 22, 2026 |
Swedish Orphan Biovitrum AB (publ)
May 27, 2026
Maintained: Buy
Price Target: kr 515.00 → kr 525.00
Current: $435.00
Upside: +20.69%
BioNTech SE
May 11, 2026
Maintained: Buy
Price Target: $155 → $140
Current: $90.80
Upside: +54.19%
Sartorius Aktiengesellschaft
Apr 24, 2026
Upgraded: Buy
Price Target: €215.00 → €250.00
Current: $229.00
Upside: +9.17%
Tecan Group AG
Apr 21, 2026
Maintained: Buy
Price Target: CHF 205.00
Current: $149.20
Upside: +37.40%
AtaiBeckley
Apr 20, 2026
Maintained: Buy
Price Target: $13 → $14
Current: $3.84
Upside: +264.58%
Qiagen
Feb 12, 2026
Maintained: Buy
Price Target: $53 → $58
Current: $37.01
Upside: +56.38%
Moderna
Jan 22, 2026
Maintained: Hold
Price Target: $26 → $32
Current: $52.13
Upside: -38.62%